MTOR and breast cancer: In summary, our investigations uncovered a hitherto unrecognized molecular and functional coupling of AKT and SOX2 proteins that determines tumorigenicity in BC, thus adding a novel perspective onto the promises and limitations of PI3K/AKT/mTOR-inhibitor therapies that are currently under laboratory and clinical investigation in BC.